Library of Citations of Selected Posters
and Abstracts
Compiled by Ronald Baker, PhD

•Protease Inhibitors
 

Darunavir (Prezista)
Saquinavir (Invirase)
Nelfinavir (Viracept)
Lopinavir/Ritonavir (Kaletra)  
Atazanavir (Reyataz)  
Fosamprenavir (Lexiva)
Tipranavir (Aptivus)

•Non Nucleoside Reverse Transcriptase Inhibitors
 

Nevirapine (Viramune)
Efavirenz (Sustiva)
Etravirine; aka TMC125 [Experimental NNRTI]

•Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
 

Tenofovir (Viread)
Abacavir (Ziagen)

•Entry Inhibitors
 

 Enfuvirtide (Fuzeon)

•Fixed-dose Combinations
 

Efavirenz 600mg + Tenofovir 300mg + Emtricitabine 200mg (Atripla)
[1 NNRTI plus 2 NRTIs]
Zidovudine 300mg + Lamivudine 150mg (Combivir) [2 RTIs]
Tenofovir 300mg + Emtricitabine 200mg (Truvada) [2 NRTIs]
Abacavir 600mg + Lamivudine 300mg (Epzicom) [2 NRTIs]
Abacavir 300mg + Zidovudine 300mg + Lamivudine 150mg (Trizivir) [3 NRTIs)

•Treatment Strategies in Treatment-experienced Patients
•Hot Topics and Late Breakers
•HIV-HCV Coinfection
Top News Articles
•Neuropsychological Symptoms in HIV-HCV Coinfected and HCV Monoinfected Individuals
•ALT Levels Poorly Predict Liver Disease in HIV-HCV Coinfected Patients
•Hepatotoxicity of Antiretroviral Therapy in HIV-HCV Coinfected Patients
•Ribavirin Plays a Critical Role in Early Virological Response in HIV-HCV Coinfected Patients
•Atazanavir has a Positive Effect on Blood Lipid Profiles
•Pegasys Plus Weight-Based Ribavirin Produces High Response Rates in HIV-HCV Coinfected Patients
•Risk Factors for Kidney Toxicity in Patients Taking Tenofovir
•Safety and Efficacy of Tenofovir + Emtricitabine + Efavirenz at 96 Weeks: Study 934
•Treatment Interruption Linked to Increased Risk of HIV Rebound
•Safety, Efficacy, and Tolerability of Protease Inhibitor Monotherapy Using Lopinavir/ritonavir
•
Two NRTI-sparing Regimens Appear Effective and Well-tolerated
•
Tenofovir Plus Trizivir Effective in a Subset of Treatment-experienced Patients
•
Effects of Antiretroviral Therapy and Metabolic Complications on Fibrosis in HIV-HCV Coinfected Patients
•
Interim Data Suggest Ritonavir-boosted Saquinavir Is as Effective as Lopinavir/ritonavir at 24 Weeks

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Links to
Website Sponsors

Glasgow City Hall